CURRENT
ISSUE
1560
November 19, 2018
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine adult immunization are discussed in a separate issue....  Continue reading
More from Issue 1560
Previous Issue: 1559      November 5, 2018
Coming Soon
Low-Dose Rivaroxaban (Xarelto) for Secondary Cardiovascular Prevention
Baloxavir Marboxil (Xofluza) - A New Drug for Treatment of Influenza
Aprepitant Emulsion (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting
Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
Drugs for Insomnia
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
Featured Article
FROM
ISSUE
1559

The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig), which targets the CGRP receptor, was the first.Continue reading